

MINUTES OF THE ANNUAL GENERAL MEETING OF THE MEDICAL TECHNOLOGY ASSOCIATION OF NEW ZEALAND, HELD AT THE CORDIS HOTEL, AUCKLAND

29 June 2022

MINUTES OF THE 2021 AGM: Minutes were circulated prior to the meeting and were taken as a true and correct record of the meeting. There were no matters arising from last minutes.

Approved: *Carmel Murphy, J&J Medtech*

Seconded: *Pieter Wijnhoud, Obex Medical*

1 PRESIDENTS REPORT

Erin Currie opened AGM with a welcome and thank you for attending the AGM. Erin then presented the following report.

[Strategic Review \(February 2022\)](#)

In our annual strategic review, we have refreshed our strategy and mission to ensure our purpose aligns with the overarching goals of the health reforms as well as responding to consistent member feedback on the need for greater impact through advocating for the industry to achieve our purpose. Our new mission is as follows:

‘To be the voice of the Med-Tech industry, influencing change and advocating for the critical role medical technology plays in improving health outcomes for all New Zealanders and a thriving economy.’

The new mission reiterates:

- That we are the ‘voice’ of the med-tech industry.
- We will ‘influence change’ through improved government affairs and advocacy activities.
- We are committed to ‘improve health outcomes’ through the use of medical technology.
- We act for ‘all’ New Zealanders in reference to the government’s goal to reduce health inequities for target groups such as Māori, Pacific and disabled people.
- Med-tech’s contribution to a ‘thriving economy’ in NZ.

A key development in the strategy is to have a greater focus on advocacy and government policy, which Cushla will speak to. The Board are committed to developing our expertise and impact in regulatory, market and investment access that affect our industry strengthen the Advisory Groups structure and focus. I recognise that this could not be possible without the contribution of knowledge, time and expertise from member companies in this area. The goal of MTANZ is utilise this contribution for all to have a strong and consistent impact. The board recognises the contribution of many individuals, with support of their organisations, to the associations work.

- Advocacy – push for need for greater effectiveness and the industry impacts that are occurring

[Board changes](#)

- The Board welcomed new member last year **John Matthews**, EBOS. We have had a stable and experienced group over the last year which has been important to support the leadership transition.
- I am pleased with the transition from this time last year for **Cushla Currie** to take the CE role. Key activities of developing workplans with the secretariat, engaging with members and potential members including utilising survey data to ensure the focus and activities of MTANZ is aligned to the value our members want.

Thank you

- Thank you, the membership, for your ongoing support and engagement. We will be doing more internal communications in the coming year to ensure you hear the issues and the work being undertaken.
- Welcome to Jacqueline Kemp, Office & Accounts Manager and I would also like to recognise Pam Thorpe who resigned in April, for her significant contribution to MTANZ over 7.5 years
- Lastly - Thank you to Cushla, Mike and Mel. For navigating a year of COVID and change and the incredible hard work for many months to hold such an event as HTW.

Approved: *Katie Noble, Allied Medical*

Seconded: *Pieter Wijnhoud, Obex Medical*

2 CHIEF EXECUTIVE OFFICER'S REPORT

Cushla Currie presented the following report:

MTANZ Member Survey Results

The results of the survey show that the current MTANZ activity members value most highly is 'providing relevant sector and industry information'. When asked what services would be most valuable in the future, 'advocacy and lobbying' was unanimously named as the most important service MTANZ can offer to members. The survey results and rapidly changing health landscape fed into the decision to realign the MTANZ structure and resources to focus more on 'Government Affairs and Policy'.

Resource Realignment

1. Advocacy and Government Affairs & Policy
 - a) New 'Head of Government Affairs' role. Mike Munley moving out of Business Development role into Head of Government Affairs role.
 - b) Initiating a new Government Affairs and Policy Special Advisory Group (GAP SAG)
 - c) Developing a 'Public Affairs' strategy.
2. Communications
 - a) Incorporating more comms into the Event Management role. Melanie Pitto will take up the comms workstream. This is focused on internal comms to members.
3. New Accounts and Office Manager - Jacqueline Kemp

Start, Stop, Continue

START

- ✓ Using the members' collective government affairs expertise via the new Special Advisory Group to improve our influence and cut through with Ministers, Political Advisors and Key Decision Makers.
- ✓ Head of Government Affairs role will form direct relationships with Ministers, Political Advisors and Key Decision Makers in order to improve visibility of key issues facing the Med-Tech industry and increase influence.
- ✓ Improve MTANZ comms internally (members) and externally (media).

STOP

- Outsource some operational event management to allow appropriate resourcing to gov. affairs and comms.

CONTINUE

- ❖ Providing relevant sector and industry information.

New Government Affairs & Policy Special Advisory Group

Name	Company	Position
Andrew Hickey	InterMed	CEO (Chair of GAP)
Mike Munley	MTANZ	Head of Gov't Affairs & Policy
Katie Noble	Allied Medical	Managing Director
Carmel Murphy	J&J Group	Gov't Affairs and Policy Manager
Paul Davies	Abbott	Director Gov't Affairs
Kate King	Medtronic	Gov't Affairs and Policy
Clinton Lubcke	Stryker	Senior Manager - Gov't Affairs
Polo Guilbert-Wright	Edwards Life	Director Gov't Affairs ANZ
Cushla Currie	MTANZ	CEO

Market Access Group

Advocacy

Alongside the work to futureproof our structure and strategy, there was a lot of engagement with government due to the many new laws passed through parliament and the Pharmac Review, therefore MTANZ made several med tech specific submissions as part of our advocacy work for members. The submissions include:

- Pae Ora (Healthy Futures) Bill,
- COVID19 Public Health Response Amendment Bill
- Pharmac Review submission

Operational

Working with the Health NZ transition teams:

- Procurement & Supply Chain
- Day One Finance Project

Key Messages

Health Technology Assessments (HTAs)

- MTANZ recommend that HTAs sit within HNZ and the MHA, accountable to the Ministry of Health, to ensure integration and alignment with the relevant equity and health target strategies.

Innovation

- The Introduction of a Rapid Access to Medical Technology Scheme – This is relevant for patients with significant unmet medical needs for target health groups or where treatments address serious or life-threatening conditions.
- Horizon Scanning for Technology Innovation – This scanning is an embedded feature of the NICE approach in the UK, the NZ government should consult the technology sector on innovation as part of a formalised structure to ensure the New Zealand system can capitalise on advances to address healthcare deficiencies and disparities. If the onus is on HNZ and MHA to improve health outcomes, this function should sit with these entities.

Focus on Patient Outcomes

- New legislation presents the opportunity for greater weighting to be placed on patient health and well-being outcomes and to broaden Pharmac's statutory objectives to include societal benefit. New legislation should ensure that all health entities including Pharmac engage with healthcare consumers sufficiently early in assessment and planning processes to ensure a genuine, non-tokenistic consultation occurs.
- Value based health procurement principles should be integrated into MBIE Government Procurement Guides and Rules of Sourcing.
- HNZ and MHA's data and digital systems should be commissioned to capture patient outcomes to facilitate Value Based Health Care implementation. This includes the ability to support decentralised care closer to home, the integration of innovation and technology, enhanced collaborative care and access to comprehensive and reliable healthcare data

Accepted: Pieter Wijnhoud, Obex Medical

Seconded: Tania Hawkes, J & J

3 FINANCIAL REPORT

Chris Isles presented the Annual Accounts for 2021-2022

- Deficit: (\$23,134), Budget (\$151,000), LY (\$75,328)
- 10% increase in Operating income over Budget
- 10% decrease in Operating expenses
- Net Assets: \$499k, down from \$522k last year
- Working Capital: 1.6x, last year 1.7x
- Clean audit report

- Budget FY23: (\$82,000)

Chris indicated that MTANZ would be reviewing the fee structures in the next six months as no changes had been made to fees in the last six years.

Questions invited from the floor – nil.

Approved: Hamish Allison, Jackson Allison

Seconded: Pieter Wijnhoud, Obex Medical

4 ELECTION OF EXECUTIVE BOARD

2021/22 Board members:

- Erin Currie, Philips
- Andrew Hickey, Intermed
- Chris Iles, Obex
- Phil Mealey, Baxter Healthcare
- Sarah Najdek, Johnson & Johnson Medtech
- Anne Familton, Becton Dickinson
- John Matthews, EBOS Healthcare

The following board members stood for re-election.

Nominations:

1. Andrew Hickey
2. Anne Familton
3. Phil Mealy

No vote was required as there were no nominations from the membership.

Election Result

1. Andrew Hickey, Intermed
2. Anne Familton, BD
3. Phil Mealy, Baxter

5 GENERAL BUSINESS

- It was questioned whether MTANZ is still the correct name for the association due to the general confusion with data and digital we heard from government officials presenting at the conference.
- It was generally agreed that a significant branding exercise is required to differentiate medical devices from data and digital to government. A name change may be part of this exercise. This will be considered by the board and fed back to members.

4.30pm AGM closed